MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/22143602241288087

Медицинская библиотека · Journal of neuromuscular diseases · 2024

Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data.

Ashrafi Mahmoud Reza, Babaee Marzieh, Hashemi Nazari Seyed Saeed, Barzegar Mohammad, Ghazavi Mohammadreza, Beiraghi Toosi Mehran, Nafissi Shahriar, Inaloo Soroor, Zamani Ghaletaki Gholamreza, Fatehi Farzad, Heshmat Ramin, Ghahvechi Akbari Masood, Abdi Alireza, Bakhtiary Hassan, Montazerlotfelahi Hadi, Abbaskhanian Ali, Hosseini Seyed Ahmad, Farshadmoghadam Hossein, Hosseiny Seyyed Mohammad Mahdi, Shariatmadari Fakhreddin, Ziaadini Bentolhoda, Babaei Meisam, Tavasoli Azita, Nikbakht Sedighe, Momen Aliakbar, Khajeh Ali, Aminzadeh Vahid, Mollamohammadi Mohsen, Taghdiri Mohammad Mehdi, Nasehi Mohammad Mehdi, Memarian Sara, Badv Reza Shervin, Heidari Morteza, Jafari Narjes

СтатьяСравнительное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Three medications have been approved for spinal muscular atrophy (SMA) treatment. No head-to-head clinical trials have directly compared the efficacy of nusinersen and risdiplam. We compare the efficacy of them in Type 2 and 3 SMA patients, with 6 months of follow-up.

METHODS

A multicenter cohort study was conducted. Demographic, genetic and clinical findings containing Hammersmith Functional Motor Scale Expanded (HFMSE) and revised upper limb module (RULM) scales were gathered. An increase of at least 3 points in HFMSE and RULM scores was considered a positive response.

RESULTS

73 (58.4%) children received risdiplam, and 52 (41.6%) received nusinersen non-randomly, based on clinical decision. The difference in HFMSE and RULM scores compared to the baseline was significant in both groups (P-value <0.001). However, there was no significant difference between mean difference changes in HFMSE and RULM scores between the two groups. 80.4% of patients in the risdiplam group and 72% in the nusinersen group achieved the 3-point cutoff after 6 months, and there is no significant difference between the two groups (P-Value:0.33).

CONCLUSIONS

This study showed that both medications significantly changed the HFSME and RULM after 3 and 6 months of follow-up. However, there was no significant difference between the two drugs according to the HFSME.

Для цитирования: Ashrafi Mahmoud Reza, Babaee Marzieh, Hashemi Nazari Seyed Saeed, Barzegar Mohammad, Ghazavi Mohammadreza, Beiraghi Toosi Mehran, Nafissi Shahriar, Inaloo Soroor, Zamani Ghaletaki Gholamreza, Fatehi Farzad, Heshmat Ramin, Ghahvechi Akbari Masood, Abdi Alireza, Bakhtiary Hassan, Montazerlotfelahi Hadi, Abbaskhanian Ali, Hosseini Seyed Ahmad, Farshadmoghadam Hossein, Hosseiny Seyyed Mohammad Mahdi, Shariatmadari Fakhreddin, Ziaadini Bentolhoda, Babaei Meisam, Tavasoli Azita, Nikbakht Sedighe, Momen Aliakbar, Khajeh Ali, Aminzadeh Vahid, Mollamohammadi Mohsen, Taghdiri Mohammad Mehdi, Nasehi Mohammad Mehdi, Memarian Sara, Badv Reza Shervin, Heidari Morteza, Jafari Narjes. Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data.. Journal of neuromuscular diseases. 2024. DOI: 10.1177/22143602241288087.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.